Loading...
XSTOCAMX
Market cap3.00bUSD
Dec 20, Last price  
563.50SEK
1D
-0.44%
1Q
-16.27%
Jan 2017
429.45%
IPO
818.63%
Name

Camurus AB

Chart & Performance

D1W1MN
XSTO:CAMX chart
P/E
76.81
P/S
19.30
EPS
7.34
Div Yield, %
0.00%
Shrs. gr., 5y
6.45%
Rev. gr., 5y
103.39%
Revenues
1.72b
+79.52%
95,204,000197,716,000208,207,000154,799,000113,737,00054,308,00049,321,000105,605,000335,997,000600,570,000956,340,0001,716,850,000
Net income
431m
+676.63%
13,317,00099,235,00048,346,000-159,542,000-80,993,000-190,574,000-234,676,000-289,865,000-167,265,000-90,446,00055,553,000431,442,000
CFO
607m
+499.69%
24,735,000163,064,00069,429,000-5,657,000-207,788,000-203,068,000-274,084,000-404,364,000-238,832,000-143,427,000101,199,000606,878,000
Earnings
Feb 13, 2025

Profile

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
URL
https://www.camurus.com/
IPO date
Dec 03, 2015
Employees
199
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,716,850
79.52%
956,340
59.24%
600,570
78.74%
Cost of revenue
1,184,495
885,812
713,851
Unusual Expense (Income)
NOPBT
532,355
70,528
(113,281)
NOPBT Margin
31.01%
7.37%
Operating Taxes
117,862
17,572
(21,322)
Tax Rate
22.14%
24.91%
NOPAT
414,493
52,956
(91,959)
Net income
431,442
676.63%
55,553
-161.42%
(90,446)
-45.93%
Dividends
Dividend yield
Proceeds from repurchase of equity
32,692
58,492
106,046
BB yield
-0.11%
-0.42%
-1.29%
Debt
Debt current
10,894
9,574
6,731
Long-term debt
38,120
42,860
44,581
Deferred revenue
(1,737)
(6,227)
Other long-term liabilities
32,612
12,532
1,019
Net debt
(1,140,826)
(520,102)
(19,883)
Cash flow
Cash from operating activities
606,878
101,199
(143,427)
CAPEX
(9,190)
(1,905)
(4,943)
Cash from investing activities
(10,127)
5,382
(4,943)
Cash from financing activities
28,763
43,705
98,904
FCF
399,617
36,479
(118,685)
Balance
Cash
1,189,840
565,539
411,575
Long term investments
6,997
(340,380)
Excess cash
1,103,998
524,719
41,166
Stockholders' equity
(551,980)
(979,062)
(1,038,487)
Invested Capital
2,102,100
2,001,727
1,900,907
ROIC
20.20%
2.71%
ROCE
34.34%
6.88%
EV
Common stock shares outstanding
57,497
55,067
54,451
Price
538.00
112.98%
252.60
67.51%
150.80
-19.10%
Market cap
30,933,648
122.39%
13,909,925
69.40%
8,211,211
-16.38%
EV
29,792,822
13,389,823
8,191,328
EBITDA
546,342
83,464
(100,600)
EV/EBITDA
54.53
160.43
Interest
1,275
1,526
1,365
Interest/NOPBT
0.24%
2.16%